Cynthia A. Jackevicius
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cynthia A. Jackevicius has a total of 301 co-authors. Here are the top co-authors by number of shared publications:
- Dennis T. Ko
University of Toronto, Toronto, ON, Canada
24 shared publications - Peter C. Austin
University of Toronto
13 shared publications - Douglas S. Lee
University of Toronto
12 shared publications Harlan M. Krumholz
Department of Internal Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut
12 shared publications- Husam Abdel-Qadir
Department of Medicine, Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network , Toronto, Ontario
9 shared publications Lingyun Lu
Department of Pharmacy (L.L., C.A.J.), Veterans Affairs Greater Los Angeles Healthcare System, CA
9 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by SAGE Publications in International Journal of Stroke
Adherence to anticoagulants in people with stroke and atrial fibrillation: Implementation of standardized analytic methods in Australia and Canada
Background: Post-stroke medication adherence can be assessed using dispensing data; however, variations in methods hinder reliable comparisons across regions. Aim: To develop and implement standardized methods to compare medication adherence to direct oral anticoagulant post-stroke between countries. Methods: An observational study was conducted across two countries participating in the International Network for Standardised Population Insights and Real-world Evidence for STROKE. Australia and Canada, with population-based linked administrative data, provided the case example. Metadata structures were shared to harmonize variables and response options in linked administrative data. Patients admitted with incident ischemic stroke and atrial fibrillation (Victoria, Australia (July 2014–June 2017); Ontario, Canada (July 2014–March 2022)), aged ⩾65 years, who survived ⩾90 days post-discharge were included. The proportion of days covered of direct oral anticoagulants was measured from initiation to 1-year post-discharge. Adherence was measured using a standardized code from the TEN-SPIDERS pharmacoepidemiology framework. Seven simulations were undertaken adjusting for different proportion of days covered measurement parameters (e.g. in-hospital stays, pre-supply, survival, and early refills and switching). Aggregated outputs were compared between countries. Results: Among 2471 Australians (50% female; 36% aged 85+ years) and 16,622 Canadians (51% female; 34% aged 85+ years), 50% and 65% were dispensed a direct oral anticoagulant within 90 days post-stroke, respectively. Among initiators, median 1-year direct oral anticoagulant proportion of days covered was 86.8% (interquartile range: 75.9–92.6%) in Australia versus 96.2% (interquartile range: 89.6–98.6%) in Canada. Simulations adjusting for pre-supply, early refills, and switching increased median proportion of days covered by +10.3% in Australia and +3.5% in Canada. Further adjustment for in-hospital stays had negligible impacts on proportion of days covered. Conclusion: Implementation of standardized methods across two countries revealed high levels of adherence to direct oral anticoagulants in patients with ischemic stroke and atrial fibrillation. Scale-up of these methods to other countries and medications is warranted to reliably measure and compare trends in post-stroke medication adherence.
- 9 September 2026
- Published by SAGE Publications in International Journal of Stroke
Open AccessAdherence to anticoagulants in people with stroke and atrial fibrillation: Implementation of standardized analytic methods in Australia and Canada
Background: Post-stroke medication adherence can be assessed using dispensing data; however, variations in methods hinder reliable comparisons across regions. Aim: To develop and implement standardized methods to compare medication adherence to direct oral anticoagulant post-stroke between countries. Methods: An observational study was conducted across two countries participating in the International Network for Standardised Population Insights and Real-world Evidence for STROKE. Australia and Canada, with population-based linked administrative data, provided the case example. Metadata structures were shared to harmonize variables and response options in linked administrative data. Patients admitted with incident ischemic stroke and atrial fibrillation (Victoria, Australia (July 2014–June 2017); Ontario, Canada (July 2014–March 2022)), aged ⩾65 years, who survived ⩾90 days post-discharge were included. The proportion of days covered of direct oral anticoagulants was measured from initiation to 1-year post-discharge. Adherence was measured using a standardized code from the TEN-SPIDERS pharmacoepidemiology framework. Seven simulations were undertaken adjusting for different proportion of days covered measurement parameters (e.g. in-hospital stays, pre-supply, survival, and early refills and switching). Aggregated outputs were compared between countries. Results: Among 2471 Australians (50% female; 36% aged 85+ years) and 16,622 Canadians (51% female; 34% aged 85+ years), 50% and 65% were dispensed a direct oral anticoagulant within 90 days post-stroke, respectively. Among initiators, median 1-year direct oral anticoagulant proportion of days covered was 86.8% (interquartile range: 75.9–92.6%) in Australia versus 96.2% (interquartile range: 89.6–98.6%) in Canada. Simulations adjusting for pre-supply, early refills, and switching increased median proportion of days covered by +10.3% in Australia and +3.5% in Canada. Further adjustment for in-hospital stays had negligible impacts on proportion of days covered. Conclusion: Implementation of standardized methods across two countries revealed high levels of adherence to direct oral anticoagulants in patients with ischemic stroke and atrial fibrillation. Scale-up of these methods to other countries and medications is warranted to reliably measure and compare trends in post-stroke medication adherence.
- 2 December 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (22) , e421-e422
Response by Abdel-Qadir et al to Letter Regarding Article, “Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study”
- 2 December 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (22) , e421-e422
Response by Abdel-Qadir et al to Letter Regarding Article, “Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study”
- Open Access
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e041185
Association of Albuminuria With 1‐Year Risk of Heart Failure and Other Adverse Outcomes in Atrial Fibrillation
Background: Albuminuria is associated with increased stroke risk in atrial fibrillation (AF), but its relationship with heart failure (HF) and other adverse outcomes in AF is less well understood. Methods: Using linked administrative databases, we conducted a retrospective cohort study of individuals aged ≥66 years who were newly diagnosed with AF between April 2009 and March 2019 in Ontario, Canada. Albuminuria was assessed using (1) urine albumin‐to‐creatinine ratio (UACR, mg/g) and (2) dipstick proteinuria (negative, trace, 1+, 2+, ≥3+). Cause‐specific hazards regression estimated adjusted hazard ratios (HRs) for HF hospitalizations or emergency department visits, stroke hospitalizations, bleeding hospitalizations, and death over 1 year. Results: We included 64 717 individuals with UACR data and 110 430 with dipstick proteinuria data. Relative to UACR 5 mg/g, the HRs for UACR 30 mg/g (below the microalbuminuria threshold) were 1.39 (95% CI, 1.28–1.50) for HF, 1.22 (95% CI, 1.07–1.40) for bleeding, and 1.35 (95% CI, 1.27–1.42) for death. A UACR of 30 mg/g versus 5 mg/g was associated with an HR of 1.16 (95% CI, 0.99–1.36) for stroke but the HR was significantly elevated at UACR values ≥65 mg/g. Increasing dipstick proteinuria was also associated with increases in the HR for adverse outcomes. A UACR of 30 mg/g was associated with greater HF risk (versus 5 mg/g) than all CHA₂DS₂VASc components except age >75 years and prior HF. Conclusions: Albuminuria is associated with increased hazards of HF, stroke, bleeding, and death in patients with AF even at low UACR levels. Albuminuria may enhance risk stratification in AF beyond traditional scores.
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e041185
Open AccessAssociation of Albuminuria With 1‐Year Risk of Heart Failure and Other Adverse Outcomes in Atrial Fibrillation
Background: Albuminuria is associated with increased stroke risk in atrial fibrillation (AF), but its relationship with heart failure (HF) and other adverse outcomes in AF is less well understood. Methods: Using linked administrative databases, we conducted a retrospective cohort study of individuals aged ≥66 years who were newly diagnosed with AF between April 2009 and March 2019 in Ontario, Canada. Albuminuria was assessed using (1) urine albumin‐to‐creatinine ratio (UACR, mg/g) and (2) dipstick proteinuria (negative, trace, 1+, 2+, ≥3+). Cause‐specific hazards regression estimated adjusted hazard ratios (HRs) for HF hospitalizations or emergency department visits, stroke hospitalizations, bleeding hospitalizations, and death over 1 year. Results: We included 64 717 individuals with UACR data and 110 430 with dipstick proteinuria data. Relative to UACR 5 mg/g, the HRs for UACR 30 mg/g (below the microalbuminuria threshold) were 1.39 (95% CI, 1.28–1.50) for HF, 1.22 (95% CI, 1.07–1.40) for bleeding, and 1.35 (95% CI, 1.27–1.42) for death. A UACR of 30 mg/g versus 5 mg/g was associated with an HR of 1.16 (95% CI, 0.99–1.36) for stroke but the HR was significantly elevated at UACR values ≥65 mg/g. Increasing dipstick proteinuria was also associated with increases in the HR for adverse outcomes. A UACR of 30 mg/g was associated with greater HF risk (versus 5 mg/g) than all CHA₂DS₂VASc components except age >75 years and prior HF. Conclusions: Albuminuria is associated with increased hazards of HF, stroke, bleeding, and death in patients with AF even at low UACR levels. Albuminuria may enhance risk stratification in AF beyond traditional scores.
- Open Access
Advancing In-Hospital Mortality Prediction for Acute Myocardial Infarction: an analysis from the American Heart Association Get-With-the-Guidelines Coronary Artery Disease Registry
Background: Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, with acute myocardial infarction (AMI) contributing to over 100,000 deaths annually in the United States. Accurate risk stratification for in-hospital mortality is essential for guiding clinical decisions, improving outcomes, and optimizing hospital resources. However, existing models often rely on limited predictor sets, outdated data, and linear methods that may not reflect current clinical practice or complex interactions. Objective: To develop and validate a contemporary in-hospital mortality risk model for AMI patients using modern statistical and machine learning approaches, incorporating clinical, demographic, and social determinants of health. Methods: We utilized data from the American Heart Association (AHA) Get with The Guidelines®– Coronary Artery Disease (GWTG-CAD) Registry. Patients with AMI admitted between October 1, 2019, and December 31, 2022 (201,191 patients from 605 hospitals) were used to develop the in-hospital mortality prediction model. An independent validation cohort included 70,302 patients admitted in 2023. We incorporated 27 predictors, including demographics, comorbidities, vital signs, laboratory values, and social determinants of health. We assessed the models including a generalized linear mixed model (GLMM) and machine learning algorithms. We benchmarked against the legacy ACTION Registry–GWTG model. Subgroup and sensitivity analyses assessed model performance across sex, race/ethnicity, STEMI status, and time period. Results: The LightGBM-based GWTG-CAD model achieved the highest discrimination (AUROC 0.874, 95% CI: 0.867–0.880) and demonstrated excellent calibration across all subgroups. Both GLMM and LightGBM outperformed the ACTION Registry–GWTG model, with LightGBM showing the most consistent performance in the 2023 validation cohort. Beyond traditional predictors, the inclusion of comorbidities, transportation methods, and community-level socioeconomic factors added predictive value. Conclusion: The new GWTG-CAD risk model incorporates clinical, pre-hospital, and social factor predictors, along with machine learning methods, to enhance prediction of mortality in contemporary AMI patients.
Open AccessAdvancing In-Hospital Mortality Prediction for Acute Myocardial Infarction: an analysis from the American Heart Association Get-With-the-Guidelines Coronary Artery Disease Registry
Background: Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, with acute myocardial infarction (AMI) contributing to over 100,000 deaths annually in the United States. Accurate risk stratification for in-hospital mortality is essential for guiding clinical decisions, improving outcomes, and optimizing hospital resources. However, existing models often rely on limited predictor sets, outdated data, and linear methods that may not reflect current clinical practice or complex interactions. Objective: To develop and validate a contemporary in-hospital mortality risk model for AMI patients using modern statistical and machine learning approaches, incorporating clinical, demographic, and social determinants of health. Methods: We utilized data from the American Heart Association (AHA) Get with The Guidelines®– Coronary Artery Disease (GWTG-CAD) Registry. Patients with AMI admitted between October 1, 2019, and December 31, 2022 (201,191 patients from 605 hospitals) were used to develop the in-hospital mortality prediction model. An independent validation cohort included 70,302 patients admitted in 2023. We incorporated 27 predictors, including demographics, comorbidities, vital signs, laboratory values, and social determinants of health. We assessed the models including a generalized linear mixed model (GLMM) and machine learning algorithms. We benchmarked against the legacy ACTION Registry–GWTG model. Subgroup and sensitivity analyses assessed model performance across sex, race/ethnicity, STEMI status, and time period. Results: The LightGBM-based GWTG-CAD model achieved the highest discrimination (AUROC 0.874, 95% CI: 0.867–0.880) and demonstrated excellent calibration across all subgroups. Both GLMM and LightGBM outperformed the ACTION Registry–GWTG model, with LightGBM showing the most consistent performance in the 2023 validation cohort. Beyond traditional predictors, the inclusion of comorbidities, transportation methods, and community-level socioeconomic factors added predictive value. Conclusion: The new GWTG-CAD risk model incorporates clinical, pre-hospital, and social factor predictors, along with machine learning methods, to enhance prediction of mortality in contemporary AMI patients.
- Open Access
- 22 April 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (6) , 432-438
Accuracy and reproducibility of ChatGPT responses to real‐world drug information questions
Introduction: The expanding use of Chat Generative Pre‐Trained Transformer (ChatGPT, OpenAI, San Francisco, CA) for drug information may enhance access to information. However, it is crucial to assess the accuracy and reproducibility of ChatGPT responses to drug information questions, examining its utility and limitations in clinical decision‐making.Objective: To evaluate the accuracy and reproducibility of ChatGPT‐3.5 and ChatGPT‐4 in responding to clinician drug information questions compared with a commonly accepted resource, Lexicomp®(Wolters Kluwer Health, Philadelphia, PA).Methods: A serial cross‐sectional study was conducted on ChatGPT from March 5 to 12, 2024 in the United States. ChatGPT‐3.5 is a free, artificial intelligence (AI) chatbot trained up to January 2022; ChatGPT‐4 is a paid‐subscription AI chatbot with internet access and more data. For trial 1 (day 0) we input 30 real‐world questions (10 drug information categories) into both ChatGPT‐3.5 and ChatGPT‐4. For trial 2 (day 1) and 3 (day 7), 10 randomly selected questions were re‐input into ChatGPT. The primary outcome evaluated the accuracy of ChatGPT‐3.5 responses versus (vs.) Lexicomp® using a 4‐point Likert scale. Secondary outcomes included assessing the accuracy of ChatGPT‐4 responses vs. Lexicomp, comparing the accuracy of both ChatGPT versions' responses, and comparing reproducibility of ChatGPT responses over time. Cohen's Kappa and Cochran's Q assessed reproducibility.Results: ChatGPT‐3.5 demonstrated 30% accuracy (9/30), while ChatGPT‐4 had 40% (12/30) accuracy (p = 0.51). Neither ChatGPT versions accurately answered all the questions in any category. ChatGPT‐3.5's agreement between trials 1 vs. 2, 1 vs. 3, and 2 vs. 3 had fair (k = 0.21), moderate (k = 0.41), and substantial agreement (k = 0.62), respectively. ChatGPT‐4 trials 1 vs. 2, 1 vs. 3, and 2 vs. 3 had fair (k = 0.23), substantial (k = 0.80), and fair agreement (0.40). The accuracy of ChatGPT‐3.5 vs. ChatGPT‐4 for the 10 questions across the three trials was 30%, 20%, and 10% (p = 0.78), and 60%, 40%, and 50% (p = 0.82).Conclusions: Both ChatGPT versions demonstrated limited accuracy and reproducibility in answering drug information questions, suggesting that health care professionals should exercise caution when using ChatGPT for drug information.
- 22 April 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (6) , 432-438
Open AccessAccuracy and reproducibility of ChatGPT responses to real‐world drug information questions
Introduction: The expanding use of Chat Generative Pre‐Trained Transformer (ChatGPT, OpenAI, San Francisco, CA) for drug information may enhance access to information. However, it is crucial to assess the accuracy and reproducibility of ChatGPT responses to drug information questions, examining its utility and limitations in clinical decision‐making.Objective: To evaluate the accuracy and reproducibility of ChatGPT‐3.5 and ChatGPT‐4 in responding to clinician drug information questions compared with a commonly accepted resource, Lexicomp®(Wolters Kluwer Health, Philadelphia, PA).Methods: A serial cross‐sectional study was conducted on ChatGPT from March 5 to 12, 2024 in the United States. ChatGPT‐3.5 is a free, artificial intelligence (AI) chatbot trained up to January 2022; ChatGPT‐4 is a paid‐subscription AI chatbot with internet access and more data. For trial 1 (day 0) we input 30 real‐world questions (10 drug information categories) into both ChatGPT‐3.5 and ChatGPT‐4. For trial 2 (day 1) and 3 (day 7), 10 randomly selected questions were re‐input into ChatGPT. The primary outcome evaluated the accuracy of ChatGPT‐3.5 responses versus (vs.) Lexicomp® using a 4‐point Likert scale. Secondary outcomes included assessing the accuracy of ChatGPT‐4 responses vs. Lexicomp, comparing the accuracy of both ChatGPT versions' responses, and comparing reproducibility of ChatGPT responses over time. Cohen's Kappa and Cochran's Q assessed reproducibility.Results: ChatGPT‐3.5 demonstrated 30% accuracy (9/30), while ChatGPT‐4 had 40% (12/30) accuracy (p = 0.51). Neither ChatGPT versions accurately answered all the questions in any category. ChatGPT‐3.5's agreement between trials 1 vs. 2, 1 vs. 3, and 2 vs. 3 had fair (k = 0.21), moderate (k = 0.41), and substantial agreement (k = 0.62), respectively. ChatGPT‐4 trials 1 vs. 2, 1 vs. 3, and 2 vs. 3 had fair (k = 0.23), substantial (k = 0.80), and fair agreement (0.40). The accuracy of ChatGPT‐3.5 vs. ChatGPT‐4 for the 10 questions across the three trials was 30%, 20%, and 10% (p = 0.78), and 60%, 40%, and 50% (p = 0.82).Conclusions: Both ChatGPT versions demonstrated limited accuracy and reproducibility in answering drug information questions, suggesting that health care professionals should exercise caution when using ChatGPT for drug information.
- Top Cited Papers
- 18 March 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (11) , 773-782
Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study
BACKGROUND: Bleeding after starting anticoagulation for atrial fibrillation (AF) may be the first sign of malignancy, especially in elderly individuals. There are no recommendations to guide investigations for malignancy after new-onset bleeding after anticoagulation for AF. Our objective was to determine the association of bleeding after starting oral anticoagulation for AF with new diagnoses of malignancy in a population-wide sample. METHODS: We conducted a population-based cohort study using linked administrative data sets of people ≥66 years of age who newly initiated warfarin or direct oral anticoagulants after diagnosis with AF between 2008 and 2022. Follow-up was 2 years after starting anticoagulation. We excluded patients with valvular disease, chronic dialysis, venous thromboembolism, previous cancer, or previously documented bleeding. Bleeding was identified from hospital/emergency department discharge records and physician billings, then handled as a time-varying covariate in cause-specific regression models while adjusting for baseline characteristics. The primary outcome was incident malignancy. We also determined the site of origin of the malignancy and the stage at diagnosis if indicated in the Ontario Cancer Registry. Analyses were repeated while limiting the exposure to specific bleeding sites. RESULTS: Among 119 480 people (mean age, 77.4 years; 52% men) who started anticoagulants, 26 037 (21.8%) had documented bleeding, and 5800 (4.9%) were diagnosed with malignancy within the next 2 years. Bleeding was associated with a higher hazard of cancer diagnosis with a hazard ratio (HR) of 4.0 (95% CI, 3.8–4.3). The HRs for any malignancy were 5.0 (95% CI, 4.6–5.5) for gastrointestinal, 5.0 (95% CI, 4.4–5.7) for genitourinary, 4.0 (95% CI, 3.5–4.6) for respiratory, 1.8 (95% CI, 1.4–2.2) for intracranial, and 1.5 (95% CI, 1.2–2.0) for nasopharyngeal bleeds. The HRs were substantially higher for cancers concordant with the bleeding site (gastrointestinal, 15.4; genitourinary, 11.8; respiratory, 10.1). Cancers were diagnosed at an earlier stage after bleeding (27.6% stage 4 after bleeding versus 31.3% without bleeding; P =0.029). CONCLUSIONS: In anticoagulated patients with AF, bleeding was strongly associated with new cancer diagnoses. Antecedent bleeding was associated with cancer diagnosis at an earlier stage. This highlights the importance of timely investigations in patients with bleeding after anticoagulation for AF, rather than attributing bleeding as an expected adverse effect.
- 18 March 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (11) , 773-782
Top Cited PapersBleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study
BACKGROUND: Bleeding after starting anticoagulation for atrial fibrillation (AF) may be the first sign of malignancy, especially in elderly individuals. There are no recommendations to guide investigations for malignancy after new-onset bleeding after anticoagulation for AF. Our objective was to determine the association of bleeding after starting oral anticoagulation for AF with new diagnoses of malignancy in a population-wide sample. METHODS: We conducted a population-based cohort study using linked administrative data sets of people ≥66 years of age who newly initiated warfarin or direct oral anticoagulants after diagnosis with AF between 2008 and 2022. Follow-up was 2 years after starting anticoagulation. We excluded patients with valvular disease, chronic dialysis, venous thromboembolism, previous cancer, or previously documented bleeding. Bleeding was identified from hospital/emergency department discharge records and physician billings, then handled as a time-varying covariate in cause-specific regression models while adjusting for baseline characteristics. The primary outcome was incident malignancy. We also determined the site of origin of the malignancy and the stage at diagnosis if indicated in the Ontario Cancer Registry. Analyses were repeated while limiting the exposure to specific bleeding sites. RESULTS: Among 119 480 people (mean age, 77.4 years; 52% men) who started anticoagulants, 26 037 (21.8%) had documented bleeding, and 5800 (4.9%) were diagnosed with malignancy within the next 2 years. Bleeding was associated with a higher hazard of cancer diagnosis with a hazard ratio (HR) of 4.0 (95% CI, 3.8–4.3). The HRs for any malignancy were 5.0 (95% CI, 4.6–5.5) for gastrointestinal, 5.0 (95% CI, 4.4–5.7) for genitourinary, 4.0 (95% CI, 3.5–4.6) for respiratory, 1.8 (95% CI, 1.4–2.2) for intracranial, and 1.5 (95% CI, 1.2–2.0) for nasopharyngeal bleeds. The HRs were substantially higher for cancers concordant with the bleeding site (gastrointestinal, 15.4; genitourinary, 11.8; respiratory, 10.1). Cancers were diagnosed at an earlier stage after bleeding (27.6% stage 4 after bleeding versus 31.3% without bleeding; P =0.029). CONCLUSIONS: In anticoagulated patients with AF, bleeding was strongly associated with new cancer diagnoses. Antecedent bleeding was associated with cancer diagnosis at an earlier stage. This highlights the importance of timely investigations in patients with bleeding after anticoagulation for AF, rather than attributing bleeding as an expected adverse effect.
- Open Access
- 10 March 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (2) , oeaf033
Post-cardiac surgery atrial fibrillation and sex differences in clinical outcomes: a systematic review and meta-analysis
There is conflicting literature on sex differences and clinical outcomes in patients who develop atrial fibrillation (AF) post-cardiac surgery. Our aim was to compare clinical outcomes between females and males with post-cardiac surgery AF. A systematic search was conducted for studies published until 27 September 2024 in MEDLINE, Embase, and CENTRAL. Included studies compared mortality and stroke in females vs. males who developed AF after cardiac surgery. Outcomes of interest were mortality and stroke. Pooled prevalence was used to compare comorbidities. Raw event rates were used to calculate odds ratios (ORs), which were pooled with a fixed-effects model. 10 422 studies were identified and 5 studies met inclusion criteria. 14 970 patients who developed AF after cardiac surgery were included, of whom 3748 were females. The length of follow-up was up to 10 years. The weighted average age was 70.4 ± 2.9 years in females and 66.7 ± 2.4 years in males (P = 0.32). At baseline, females had a higher prevalence of hypertension, diabetes, dyslipidemia, stroke, and peripheral vascular disease. The odds of in-hospital mortality among females were higher compared to males (5.5 vs. 3.0%; OR 2.04, 95% CI 1.42–2.91, P < 0.001, I2 = 57%). There were no significant differences in post-discharge mortality (45.6 vs. 42.9%; OR 1.05, 95% CI 0.97–1.15, P = 0.23, I2 = 0%) or in-hospital stroke (2.5 vs. 1.9%; OR 1.30, 95% CI 0.79–2.13, P = 0.30, I2 = 57%) in females vs. males. In conclusion, females with post-cardiac surgery AF had a higher prevalence of comorbidities at baseline. The odds of in-hospital mortality were twice as high among females. There were no significant differences in post-discharge mortality or in-hospital stroke. Future studies are warranted to understand the mechanisms of increased in-hospital mortality in females and to develop effective monitoring strategies and interventions.
- 10 March 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (2) , oeaf033
Open AccessPost-cardiac surgery atrial fibrillation and sex differences in clinical outcomes: a systematic review and meta-analysis
There is conflicting literature on sex differences and clinical outcomes in patients who develop atrial fibrillation (AF) post-cardiac surgery. Our aim was to compare clinical outcomes between females and males with post-cardiac surgery AF. A systematic search was conducted for studies published until 27 September 2024 in MEDLINE, Embase, and CENTRAL. Included studies compared mortality and stroke in females vs. males who developed AF after cardiac surgery. Outcomes of interest were mortality and stroke. Pooled prevalence was used to compare comorbidities. Raw event rates were used to calculate odds ratios (ORs), which were pooled with a fixed-effects model. 10 422 studies were identified and 5 studies met inclusion criteria. 14 970 patients who developed AF after cardiac surgery were included, of whom 3748 were females. The length of follow-up was up to 10 years. The weighted average age was 70.4 ± 2.9 years in females and 66.7 ± 2.4 years in males (P = 0.32). At baseline, females had a higher prevalence of hypertension, diabetes, dyslipidemia, stroke, and peripheral vascular disease. The odds of in-hospital mortality among females were higher compared to males (5.5 vs. 3.0%; OR 2.04, 95% CI 1.42–2.91, P < 0.001, I2 = 57%). There were no significant differences in post-discharge mortality (45.6 vs. 42.9%; OR 1.05, 95% CI 0.97–1.15, P = 0.23, I2 = 0%) or in-hospital stroke (2.5 vs. 1.9%; OR 1.30, 95% CI 0.79–2.13, P = 0.30, I2 = 57%) in females vs. males. In conclusion, females with post-cardiac surgery AF had a higher prevalence of comorbidities at baseline. The odds of in-hospital mortality were twice as high among females. There were no significant differences in post-discharge mortality or in-hospital stroke. Future studies are warranted to understand the mechanisms of increased in-hospital mortality in females and to develop effective monitoring strategies and interventions.
- Open Access
- 1 July 2024
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 39 (13) , 2522-2530
Non-Inferiority Trials: A Systematic Review on Methodological Quality and Reporting Standards
Background: Non-inferiority (NI) trials require unique trial design and methods, which pose challenges in their interpretation and applicability, risking introduction of inferior therapies in clinical practice. With the abundance of novel therapies, NI trials are increasing in publication. Prior studies found inadequate quality of reporting of NI studies, but were limited to certain specialties/journals, lacked NI margin evaluation, and did not examine temporal changes in quality. We conducted a systematic review without restriction to journal type, journal impact factor, disease state or intervention to evaluate the quality of NI trials, including a comprehensive risk of bias assessment and comparison of quality over time. Methodology: We searched PubMed and Cochrane Library databases for NI trials published in English in 2014 and 2019. They were assessed for: study design and NI margin characteristics, primary results, and risk of bias for blinding, concealment, analysis method and missing outcome data. Results: We included 823 studies. Between 2014 and 2019, a shift from publication in specialty to general journals (15% vs 28%, p < 0.001) and from pharmacological to non-pharmacological interventions (25% vs 38%, p = 0.025) was observed. The NI margin was specified in most trials for both years (94% vs 95%). Rationale for the NI margin increased (36% vs 57%, p < 0.001), but remained low, with clinical judgement the most common rationale (30% vs 23%), but more 2019 articles incorporating patient values (0.3% vs 21%, p < 0.001). Over 50% of studies were open-label for both years. Gold standard method of analyses (both per protocol + (modified) intention to treat) declined over time (43% vs 36%, p < 0.001). Discussion: The methodological quality and reporting of NI trials remains inadequate although improving in some areas. Improved methods for NI margin justification, blinding, and analysis method are warranted to facilitate clinical decision-making.
- 1 July 2024
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 39 (13) , 2522-2530
Open AccessNon-Inferiority Trials: A Systematic Review on Methodological Quality and Reporting Standards
Background: Non-inferiority (NI) trials require unique trial design and methods, which pose challenges in their interpretation and applicability, risking introduction of inferior therapies in clinical practice. With the abundance of novel therapies, NI trials are increasing in publication. Prior studies found inadequate quality of reporting of NI studies, but were limited to certain specialties/journals, lacked NI margin evaluation, and did not examine temporal changes in quality. We conducted a systematic review without restriction to journal type, journal impact factor, disease state or intervention to evaluate the quality of NI trials, including a comprehensive risk of bias assessment and comparison of quality over time. Methodology: We searched PubMed and Cochrane Library databases for NI trials published in English in 2014 and 2019. They were assessed for: study design and NI margin characteristics, primary results, and risk of bias for blinding, concealment, analysis method and missing outcome data. Results: We included 823 studies. Between 2014 and 2019, a shift from publication in specialty to general journals (15% vs 28%, p < 0.001) and from pharmacological to non-pharmacological interventions (25% vs 38%, p = 0.025) was observed. The NI margin was specified in most trials for both years (94% vs 95%). Rationale for the NI margin increased (36% vs 57%, p < 0.001), but remained low, with clinical judgement the most common rationale (30% vs 23%), but more 2019 articles incorporating patient values (0.3% vs 21%, p < 0.001). Over 50% of studies were open-label for both years. Gold standard method of analyses (both per protocol + (modified) intention to treat) declined over time (43% vs 36%, p < 0.001). Discussion: The methodological quality and reporting of NI trials remains inadequate although improving in some areas. Improved methods for NI margin justification, blinding, and analysis method are warranted to facilitate clinical decision-making.
- Open Access
- 1 May 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 226, 134-136
Comparing Measures of Adherence and Persistence to P2Y12 Inhibitors in Acute Coronary Syndromes
- 1 May 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 226, 134-136
Open AccessComparing Measures of Adherence and Persistence to P2Y12 Inhibitors in Acute Coronary Syndromes
- Open Access
- 16 April 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (8) , e030140
Evaluating Readability, Understandability, and Actionability of Online Printable Patient Education Materials for Cholesterol Management: A Systematic Review
Background: Dyslipidemia management is a cornerstone in cardiovascular disease prevention and relies heavily on patient adherence to lifestyle modifications and medications. Numerous cholesterol patient education materials are available online, but it remains unclear whether these resources are suitable for the majority of North American adults given the prevalence of low health literacy. This review aimed to (1) identify printable cholesterol patient education materials through an online search, and (2) evaluate the readability, understandability, and actionability of each resource to determine its utility in practice. Methods and Results: We searched the MEDLINE database for peer‐reviewed educational materials and the websites of Canadian and American national health organizations for gray literature. Readability was measured using the Flesch–Kincaid Grade Level, and scores between fifth‐ and sixth‐grade reading levels were considered adequate . Understandability and actionability were scored using the Patient Education Materials Assessment Tool and categorized as superior (>80%), adequate (50%–70%), or inadequate (<50%). Our search yielded 91 results that were screened for eligibility. Among the 22 educational materials included in the study, 15 were identified through MEDLINE, and 7 were from websites. The readability across all materials averaged an 11th‐grade reading level (Flesch–Kincaid Grade Level=11.9±2.59). The mean±SD understandability and actionability scores were 82.8±6.58% and 40.9±28.60%, respectively. Conclusions: The readability of online cholesterol patient education materials consistently exceeds the health literacy level of the average North American adult. Many resources also inadequately describe action items for individuals to self‐manage their cholesterol, representing an implementation gap in cardiovascular disease prevention.
- 16 April 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (8) , e030140
Open AccessEvaluating Readability, Understandability, and Actionability of Online Printable Patient Education Materials for Cholesterol Management: A Systematic Review
Background: Dyslipidemia management is a cornerstone in cardiovascular disease prevention and relies heavily on patient adherence to lifestyle modifications and medications. Numerous cholesterol patient education materials are available online, but it remains unclear whether these resources are suitable for the majority of North American adults given the prevalence of low health literacy. This review aimed to (1) identify printable cholesterol patient education materials through an online search, and (2) evaluate the readability, understandability, and actionability of each resource to determine its utility in practice. Methods and Results: We searched the MEDLINE database for peer‐reviewed educational materials and the websites of Canadian and American national health organizations for gray literature. Readability was measured using the Flesch–Kincaid Grade Level, and scores between fifth‐ and sixth‐grade reading levels were considered adequate . Understandability and actionability were scored using the Patient Education Materials Assessment Tool and categorized as superior (>80%), adequate (50%–70%), or inadequate (<50%). Our search yielded 91 results that were screened for eligibility. Among the 22 educational materials included in the study, 15 were identified through MEDLINE, and 7 were from websites. The readability across all materials averaged an 11th‐grade reading level (Flesch–Kincaid Grade Level=11.9±2.59). The mean±SD understandability and actionability scores were 82.8±6.58% and 40.9±28.60%, respectively. Conclusions: The readability of online cholesterol patient education materials consistently exceeds the health literacy level of the average North American adult. Many resources also inadequately describe action items for individuals to self‐manage their cholesterol, representing an implementation gap in cardiovascular disease prevention.